http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102181740-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-102181740-B1 |
titleOfInvention | Use of YDJC in lung cancer |
abstract | The present invention is a biomarker composition using YDJC (Chitooligosaccharide deacetylase homolog), a composition for diagnosing lung cancer or predicting the prognosis of metastasis, a kit comprising the composition, a method of providing information necessary for diagnosing lung cancer or predicting the prognosis of metastasis. Pharmaceutical composition for treating lung cancer , And a method for screening lung cancer treatment or metastasis inhibitors.In the present invention, it was found that YDJC induces EMT and promotes lung cancer progression.By measuring the expression level of YDJC, early diagnosis of lung cancer or prediction of metastasis prognosis It is possible to treat and develop useful lung cancer treatments through lung cancer treatment or screening for metastasis inhibitors, so it is expected to be useful in the medical industry. |
priorityDate | 2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 356.